Mirati Therapeutics (NASDAQ:MRTX) Trading Down 5.2% Following Analyst Downgrade

Mirati Therapeutics Inc (NASDAQ:MRTX) was down 5.2% on Monday after B. Riley lowered their price target on the stock from $92.00 to $83.00. B. Riley currently has a neutral rating on the stock. Mirati Therapeutics traded as low as $82.48 and last traded at $82.70, approximately 1,633,463 shares were traded during mid-day trading. An increase of 147% from the average daily volume of 661,629 shares. The stock had previously closed at $87.27.

MRTX has been the subject of several other research reports. Jefferies Financial Group upgraded Mirati Therapeutics from a “hold” rating to a “buy” rating and raised their target price for the stock from $89.00 to $105.00 in a research note on Monday. Cowen restated a “buy” rating on shares of Mirati Therapeutics in a research report on Tuesday, August 6th. Guggenheim cut shares of Mirati Therapeutics from a “buy” rating to a “neutral” rating and set a $95.56 price objective for the company. in a research note on Friday, June 7th. HC Wainwright reaffirmed a “buy” rating and set a $117.00 target price on shares of Mirati Therapeutics in a report on Tuesday, August 6th. Finally, Piper Jaffray Companies upped their target price on shares of Mirati Therapeutics from $85.00 to $125.00 and gave the stock an “overweight” rating in a report on Tuesday, June 4th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $98.60.

In other news, major shareholder Avoro Capital Advisors Llc sold 62,500 shares of the stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $101.88, for a total value of $6,367,500.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Michael G. Grey sold 3,042 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $92.27, for a total transaction of $280,685.34. Following the sale, the director now owns 4,840 shares in the company, valued at approximately $446,586.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 845,360 shares of company stock valued at $82,651,250. Corporate insiders own 4.70% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Atria Investments LLC bought a new position in shares of Mirati Therapeutics during the 2nd quarter valued at about $1,062,000. BlackRock Inc. boosted its stake in shares of Mirati Therapeutics by 8.6% in the 2nd quarter. BlackRock Inc. now owns 2,536,034 shares of the biotechnology company’s stock valued at $261,211,000 after purchasing an additional 199,939 shares in the last quarter. Chartwell Investment Partners LLC bought a new position in shares of Mirati Therapeutics during the 2nd quarter valued at $1,864,000. Perceptive Advisors LLC grew its holdings in shares of Mirati Therapeutics by 149.0% during the 2nd quarter. Perceptive Advisors LLC now owns 2,899,606 shares of the biotechnology company’s stock valued at $298,659,000 after purchasing an additional 1,735,224 shares during the last quarter. Finally, University of Notre Dame DU Lac bought a new position in shares of Mirati Therapeutics during the 2nd quarter valued at $5,405,000.

The company has a market cap of $3.19 billion, a PE ratio of -26.81 and a beta of 2.07. The business’s 50-day moving average is $90.90 and its 200 day moving average is $83.56.

Mirati Therapeutics (NASDAQ:MRTX) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.18) by ($0.08). The business had revenue of $0.58 million for the quarter. As a group, equities research analysts predict that Mirati Therapeutics Inc will post -5.08 EPS for the current fiscal year.

About Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.

Featured Article: Example of operating income, EBIT and EBITDA

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit